24/7 Market News Snapshot 19 March, 2025 – FOXO Technologies Inc. (NYSE:FOXO)

March 19, 2025

DENVER, Colo., 19 March, 2025 (247marketnews.com) – (NYSE:FOXO) are discussed in this article.
FOXO Technologies Inc. (NASDAQ:FOXO) is experiencing a significant surge in pre-market trading, with shares currently priced at $0.183, reflecting an increase of 18.83% from the previous close of $0.154. This momentum is underscored by a notable trading volume of 9.06 million shares, indicating increased investor interest and a potential bullish trend. Analysts will be attentive to crucial support levels around $0.154 and resistance points near $0.20. The observed price action suggests a strong bullish sentiment that may be driven by recent developments, including expectations surrounding the company’s future performance. Continuous monitoring of trading volume and price movements will be critical in assessing the sustainability of this upward trajectory or the risk of a price correction.

In a groundbreaking strategic move, FOXO Technologies has also announced a non-binding agreement to acquire Vector Biosource Inc., a prominent provider of information and biospecimen sourcing for the biotechnology and pharmaceutical sectors. This acquisition is aimed at expanding FOXO’s healthcare capabilities and unlocking new growth avenues. Vector Biosource is projected to generate approximately $800,000 in revenue for the year 2025, highlighting its robust market presence. The agreement stipulates an acquisition price consisting of $750,000 in the stated value of FOXO’s Series D Cumulative Redeemable Preferred Stock and an additional $750,000 contingent on achieving specific revenue and cash collection benchmarks in 2025.

Seamus Lagan, FOXO’s CEO, expressed enthusiasm for the partnership, emphasizing the alignment of Vector’s growth potential with FOXO’s strategic objectives. Frank Dias, Jr., CEO of Vector, also acknowledged the advantages this collaboration offers for bolstering growth through enhanced resources and corporate infrastructure. The transaction is anticipated to close within the next 45 days, pending the execution of definitive agreements and satisfactory due diligence. This acquisition represents a strategic step forward for FOXO, reinforcing its commitment to innovation within the biotechnology sector.

Related news for (FOXO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.